Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

4.575 -0.065 (-1.40%)
Streaming Delayed Price Updated: 1:23 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Research License with Catalent
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Lisata Therapeutics ↗
 
Via Benzinga
News headline image
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales ↗
 
Via Benzinga
News headline image
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
US Stocks Higher; Netflix Profit Beats Estimates ↗
 
Via Benzinga
News headline image
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
News headline image
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.